Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Jones, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Vienna, Austria
- Facility name not stated
Nanjing, Jiangsu, China
- Facility name not stated
Chengdu, Sichuan, China
- Facility name not stated
Hangzhou, Zhejiang, China
- Facility name not stated
Beijing, China
- Facility name not stated
Angers, France
- Facility name not stated
Paris, France
- Facility name not stated
Pierre-Bénite, France
- Facility name not stated
Leipzig, Germany
- Facility name not stated
Florence, Italy
- Facility name not stated
Milan, Italy
- Facility name not stated
Terni, Italy
- Facility name not stated
Rotterdam, Netherlands
- Facility name not stated
Belfast, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Winter Park, Florida, United States
- Facility name not stated
Baltimore, Maryland, United States
- Facility name not stated
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2011
- Primary completion
- 31 Dec 2019
- Completion
- 31 Dec 2019
- Last update posted
- 22 Aug 2025
- Registered enrollment
- 69
- Registry id
- NCT01317875
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.